Digital Health Investment Weekly Report Vol.164: Highlights and Product Updates
Pathos AI
Biotechnology Developer
Cohere Health
Healthcare Service Process Management Platform Developer
Juvenescence
Developer of Therapies for Aging and Age-Related Diseases
Akido Labs
Developer of Artificial Intelligence Technology for Healthcare
01 Global Digital Health Investment and Financing Overview
AI-Driven Biopharmaceutical Company Pathos AI Secures $365 Million in Series D Funding
On May 15, Pathos AI, an AI-driven biopharmaceutical company, secured $365 million in Series D funding. The proceeds will be used to advance the company's clinical-stage pipeline and continue investment in its AI foundational model specifically designed for oncology, aiming to accelerate the speed, precision, and success rate of cancer drug development.
Cohere Health, a developer of healthcare service process management platforms, secures $90 million in Series C funding
On May 14, Cohere Health, a developer of healthcare service process management platforms, secured $90 million in Series C funding led by Temasek, with continued support from Deerfield Management, Define Ventures, and others. The funds will be used to expand its AI-based platform, scale up the Cohere Unify™ platform, explore new clinical application scenarios, and increase investment in its AI-driven product portfolio.
Aging and Age-Related Disease Therapies Developer Juvenescence Secures $76 Million in B-1 Funding Round
On May 21, Juvenescence, a developer of therapies for aging and age-related diseases, secured a $76 million B-1 round of financing led by M42, with follow-on investments from existing investors. This funding will enable Juvenescence to continue advancing its therapeutic portfolio into clinical development and provide critical clinical readouts for its core drug pipeline.
Women's Health Company ReproNovo Secures $65 Million in Series A Funding
On May 21, women's health company ReproNovo secured $65 million in Series A financing, led by Jeito Capital, with AXA IM Alts and M Ventures as co-leads, and participation from Ysios Capital and ALSA Ventures. The funds will be used to advance its pipeline of multiple Phase II clinical projects, focusing on developing innovative therapies for treating male and female infertility as well as uterine health issues.
Akido Labs, a developer of artificial intelligence technology for healthcare, raises $60 million in Series B funding
On May 15, Akido Labs, a developer of artificial intelligence technology for healthcare, secured $60 million in Series B funding. The round was led by Oak HC/FT, with participation from Greco, SNR, and existing investors Y Combinator, Future Communities Capital, Jeff Dean, and Comprehensive Blood & Cancer Center. The funds will be used to expand the reach of its breakthrough health AI system, ScopeAI, enhance clinical capabilities, and improve healthcare accessibility.
Mobile Healthcare Service Provider Sprinter Health Raises $55 Million in Series B Funding
On May 15, mobile healthcare service provider Sprinter Health secured a $55 million Series B funding round led by General Catalyst, with participation from Andreessen Horowitz (a16z) Bio + Health and other existing investors. The funds will be used to expand its technology stack, broaden service offerings, and attract more people from communities across China to increase the reach of preventive healthcare and address critical healthcare gaps.
Alpheus Medical, a developer of novel sonodynamic therapy devices, secures $52 million in Series B funding
On May 15, Alpheus Medical, a developer of novel sonodynamic therapy devices, secured $52 million in Series B funding, co-led by HealthQuest Capital and Samsara BioCapital, with participation from existing investors OrbiMed and Action Potential Venture Capital. The funds will be used to advance its groundbreaking glioblastoma treatment technology and support a randomized controlled trial (RCT) for newly diagnosed glioblastoma patients.
Liquid Biopsy Diagnostic Technology Developer Indical Bioscience Secures $34 Million in Series A Funding
On May 20, liquid biopsy diagnostic technology developer Indx Bio completed a $34 million Series A financing round, led by a private equity fund under Value Partners Group, with active participation from multiple new investors and continued support from existing investors. The funds will be used to accelerate the launch of next-generation urine testing diagnostic products, advance the development of its exclusive patented PHASIFY™ urine concentration technology, and further expand non-invasive diagnostic solutions in the fields of early disease screening, women's health, and infectious diseases.
Healthcare Technology Service Provider Dazos Secures $25 Million in Series A Funding
On May 19, healthcare technology service provider Dazos secured $25 million in Series A funding, invested by Radian Capital based in New York. This round of financing will be used to accelerate product development and deepen support for its growing customer base.
Life Science Instrument and Biopharmaceutical Equipment Developer, Lead Health, Secures Nearly RMB100 Million in Angel Round Financing
On May 22, Lider Health, a developer of life science instruments and biopharmaceutical equipment, secured nearly RMB 100 million in angel funding. The round was led by Guidao Capital, with participation from Qi Ji Investment, Zhongke Chuangxing, Juke New Industry Venture Capital, Jian Shi Capital, and Jiuzhou Xinnuo. The proceeds will be used to accelerate technology research and development, product industrialization, and market expansion.
Biotechnology Service Provider CHUANGXIN International Secures Nearly RMB 100 Million in Series B Financing
On May 19, biotechnology service provider Creative International secured nearly RMB 100 million in a Series B funding round, jointly led by Yueke Fund and Zhongshan Haichuang Fund under Toukong Donghai. The funds will be used to accelerate the R&D transformation of organoid technology and its global commercial layout.
Reperio Health, a Provider of Family Health Assessment and Biometric Screening Systems, Raises $14 Million
On May 21, Reperio Health, a provider of family health assessment and biometric screening systems, secured $14 million in funding led by Caduceus Capital Partners. The funds will be used to expand its home-based preventive care solutions across all 50 states in the U.S., enhance its AI-assisted real-time virtual care capabilities, and increase participation in preventive care.
AI Biostate AI Secures $12 Million in Series A Funding
On May 20, Biostate AI, an AI biometric data research company, secured $12 million in Series A funding led by Accel, with participation from Gaingels, Mana Ventures, InfoEdge Ventures, and existing investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures. The funds will be used to support its mission of unlocking affordable and comprehensive precision medicine, starting with RNA sequencing (RNAseq) services based on molecular research in the U.S.
AI-Driven Drug Formulation Company Persist AI Secures $12 Million in Series A Funding
On May 19, AI-driven drug formulation company Persist AI secured $12 million in Series A funding, led by Spero Ventures with participation from MBX Capital, Shimadzu Future Innovation Fund, Eli Lilly and Company, and others. The funds will be used to accelerate the development of its innovative cloud-based laboratory platform, which is capable of reducing drug formulation development time from years to months.
Pulmonary Hypertension Device Developer Pulnovo Medical Secures $10 Million in Financing
On May 21, Pulmonary Hypertension Treatment Device Developer Pulnovo Medical Secures $10 Million in Financing Led by European Trillion-Level Private Equity Firm EQT, with Continued Support from Qiming Venture Partners. The funds will primarily be used for Pulnovo Medical's overseas market expansion and advancement, including global clinical registration, product indication expansion, and deepening of the industrialization system.
Radiology Diagnostic Services Provider Rad AI Secures $8 Million in Series C Funding
On May 20, Radiology diagnostic services provider Rad AI secured an $8 million Series C funding round led by Advocate Health, Memorial Hermann Health System, Corewell Health, and Atlantic Health System. The funds will be used to expand the application of generative artificial intelligence in hospitals and clinics, improving radiologists' work efficiency and the quality of patient care.
Viz.ai Collaborates with Sanofi and Regeneron to Improve COPD Care Using Artificial Intelligence
On May 21, Viz.ai entered into a multi-year collaboration with global healthcare company Sanofi and biotechnology company Regeneron to improve the management of chronic obstructive pulmonary disease (COPD) using artificial intelligence (AI) technology. The collaboration will focus on evaluating an AI-driven care coordination tool designed to enhance the detection and treatment of high-risk COPD patients. Viz.ai will deploy its COPD module, leveraging electronic health record (EHR) data and AI to identify patients in need of timely intervention, helping healthcare providers streamline workflows for faster and more efficient care.
DuPont Collaborates with Epicore Bio to Enhance Worker Safety through Smart Wearable Technology
On May 20, DuPont Personal Protection (DuPont) partnered with digital health solutions provider Epicore Bio to explore opportunities for enhancing worker safety and well-being through smart wearable technology. DuPont brings expertise in protective clothing, while Epicore offers advanced wearable hydration management technology. The collaboration aims to address the risks posed by rising temperatures and extreme climate conditions to workers, particularly in physically demanding industries.
Merck Collaborates with IMEC to Develop Microphysiological Systems Platform
On May 20, Merck and IMEC entered into a strategic partnership to jointly develop an advanced Microphysiological Systems (MPS) platform. This collaboration aims to gradually reduce reliance on animal testing by enhancing the predictive effectiveness of next-generation preclinical models, thereby improving the efficiency of drug discovery and development. The partnership combines Merck’s portfolio of induced pluripotent stem cells and patient-derived organoids with IMEC’s groundbreaking hardware platform, creating a pipeline that bridges in vitro and in silico environments to generate high-quality biological training data. Integrated with AI-driven drug discovery, this closed-loop operational model will enhance data translatability, accelerate the identification of new drug candidates, and more closely simulate the human body.
Mental Health and Addiction Recovery Platform Recovery.com Acquires RedFox AI
On May 21, mental health and addiction recovery platform Recovery.com acquired RedFox AI, an artificial intelligence startup. This acquisition solidified Recovery.com's mission to streamline access to mental health and addiction treatment and laid the foundation for developing new AI-driven tools to better connect people with care services.
IT and Health Technology Education Service Company Neusoft Rixin Acquires Xikang Cloud House
On May 20, IT and health education service provider Neusoft Rixin (9616.HK) acquired Xikang Cloud House, a provider of medical rehabilitation and nutrition health consulting services. This move will further strengthen the group's "healthcare tourism" business resource integration, promote the distinctive development of elderly education, and expand university practical education platforms. This acquisition is a key step in perfecting the group’s "education, healthcare, eldercare, rehabilitation, and healthcare tourism" strategic layout, fully reflecting its strategic determination to advance the integration and development of the five major business ecosystems.
Hangzhou State-owned Capital Acquires Neuroelectronic Medical Device Manufacturer Nurotron for Hundreds of Millions of Yuan
On May 16, an investment platform under Hangzhou State-owned Capital Investment & Operation and Hangzhou Yuhang Financial Holding Group acquired NeuroElectronics, a producer of neuroelectronic medical devices, for hundreds of millions of yuan. This layout by state-owned capital will further improve the governance structure of NeuroElectronics, accelerate its global strategy and the long-term development of its neuroelectronic business, and promote its deep integration into the industrial ecosystem of Hangzhou's Western Science and Technology Corridor.
Molecular Testing and Diagnostic Product Developer Qiagen Acquires Genoox for $80 Million
On May 14, molecular testing and diagnostic product developer Qiagen acquired clinical genomic interpretation software company Genoox for $70 million in cash and up to $10 million in additional milestone payments. Genoox's flagship product, Franklin, is a clinical genomic data analysis and interpretation reporting software that has been used by more than 4,000 medical institutions across 50 countries worldwide. This acquisition will enhance Qiagen's clinical decision support capabilities and is expected to generate approximately $5 million in revenue for Qiagen in 2025.
Artery Network/Arterial Orange Industry Think Tank/Huaxing Capital/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Share
Like
Tap to view